NeoDynamics introduces US FDA approved pulse biopsy technology, NeoNavia for breast and axillary lymph node biopsies
NeoDynamics, Inc., a MedTech company, announced the US availability of NeoNavia, the first and only biopsy system built on a patented pulse technology for controlled and precise needle insertion.
NeoNavia will be commercially introduced at The American Society of Breast Surgeons (ASBrS) 24th Annual Meeting at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts through Sunday and the following week, at the SBI Breast Imaging Symposium, May 4-7, 2023, at the Gaylord National Resort & Convention Center in National Harbor, Maryland. ASBrS serves as the primary leadership organization for general surgeons who treat patients with breast disease and has grown to more than 3,000 members in the United States and 35 countries throughout the world. SBI is the leading network of breast radiologists and medical physicists in the US.
The NeoDynamics commercial team will be providing hands-on workshops and demonstrations of the NeoNavia system to demonstrate the precision and control with pulse technology as well as the FlexiPulse retractable, open-tip needle which produces up to a 299% larger sample than side-notch core needle systems.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!